Epstein Secrets

e relatively low bar used this year for emergency use authorization for treatments." Calling the meeting "an usual step," the AE (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust and confi

rious maladies are still under review and dismissed claims that American workers were not adequately protected." Also reporting is fax News (10/22, McKay, 27.59M). Intelligence Officials Warning About Election Interference Earlier Than In 2016. Carrie Cordero, a "senior fellow at the Center for a New

ents." Calling the meeting "an usual step," the AP <https://apnews.corn/article/virus-outbreak- e49203f5c55ba593ca587a56d0116b97> (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust and confid

g is Fox News <https://www.foxnews.corn/world/us-officials-were-targeted-across-the-world-including-american-soil-by- seeming-sonic-attacks> (10/22, McKay, 27.59M). Intelligence Officials Warning About Election Interference Earlier Than In 2016. Carrie Cordero, a "senior fellow at the Center for a New

e relatively low bar used this year for emergency use authorization for treatments." Calling the meeting "an usual step," the AP (10/22, Neergaard, Perrone) reports Dr. Marion Gruber, director of FDA's vaccine research office, told the advisers that public scrutiny "is critical to build trust and confi

erious maladies are still under review and dismissed claims that American workers were not adequately protected." Also reporting is Fox News (10/22, McKay, 27.59M). Intelligence Officials Warning About Election Interference Earlier Than In 2016. Carrie Cordero, a "senior fellow at the Center for a New

(11/30, Staff Writer) and The Epoch Times (11/30, Nguyen Ly). US Panel Backs First-Of-A-Kind COVID-19 Pill From Merck The Associated Press (11/30, Perrone) reported that a panel of Food and Drug Administration (FDA) health advisers voted 13-10 in support of Merck's new COVID-19 pill, molnupiravir, stat

dn't be used in vaccinated people, who weren't part of Merck's research and haven't been shown to benefit!' The Wall Street Journal (11/30, Hopkins, McKay) reported that according to a final analysis, the drug was found to be 30% effective at reducing the risk of hospitalization and death in high-risk